Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

Laura M. Epple, Lynne T. Bemis, Ryan P. Cavanaugh, Anne Skope, Tehila Mayer-Sonnenfeld, Chad Frank, Christine S. Olver, Alex M. Lencioni, Nathaniel L. Dusto, Alona Tal, Michael Har-Noy, Kevin O. Lillehei, Emmanuel Katsanis, Michael W. Graner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: This paper presents the treatment of a 12-year-old female spayed Great Dane who presented with vestibular signs (ataxia, nystagmus, hind end collapse). Thoracic radiographs revealed a discrete pulmonary nodule in the right cranial lung lobe. Ultrasound-guided fine needle aspirate detected primary bronchoalveolar adenocarcinoma, verified via computed tomography, with a second smaller nodule discovered in the right cranial lung lobe. Materials and methods: A lateral thoracotomy with right cranial lung lobectomy was performed. Histopathological analysis of the nodules and an excised lymph node identified grade III bronchoalveolar adenocarcinoma with vascular infiltration and lymph node metastasis-a grim diagnosis with a reported median survival time of 6-27 days. A 10-g sample of the tumour was processed into a chaperone-rich cell lysate (CRCL) vaccine, which was administered weekly to the patient. Imiquimod-a Toll-like receptor 7 (TLR7) agonist-was applied topically for the first 12 treatments to stimulate local Langerhans cells. A single injection of bacillus Calmette-Guerin (BCG) was administered for additional immune stimulation at week 30 of treatment. Results: The dog remained stable and in otherwise good health until diffuse relapse occurred 44 weeks after the initial treatment; following gastrointestinal bleeding, the dog was euthanised 50+ weeks post diagnosis. Conclusion: To the authors' knowledge, this is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case report suggests that CRCL vaccine combined with topical imiquimod is a safe, effective treatment for canine tumours.

Original languageEnglish (US)
Pages (from-to)390-398
Number of pages9
JournalInternational Journal of Hyperthermia
Volume29
Issue number5
DOIs
StatePublished - Aug 2013

Fingerprint

Adenocarcinoma
Vaccines
imiquimod
Dogs
Lung
Neoplasms
Canidae
Toll-Like Receptor 7
Lymph Nodes
Combined Vaccines
Therapeutics
Survival
Langerhans Cells
Thoracotomy
Ataxia
Mycobacterium bovis
Needles
Blood Vessels
Thorax
Tomography

Keywords

  • Cancer vaccine
  • Canine lung tumour
  • Chaperone-rich cell lysate
  • Heat shock proteins
  • Tumour immunity

Cite this

Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. / Epple, Laura M.; Bemis, Lynne T.; Cavanaugh, Ryan P.; Skope, Anne; Mayer-Sonnenfeld, Tehila; Frank, Chad; Olver, Christine S.; Lencioni, Alex M.; Dusto, Nathaniel L.; Tal, Alona; Har-Noy, Michael; Lillehei, Kevin O.; Katsanis, Emmanuel; Graner, Michael W.

In: International Journal of Hyperthermia, Vol. 29, No. 5, 08.2013, p. 390-398.

Research output: Contribution to journalArticle

Epple, LM, Bemis, LT, Cavanaugh, RP, Skope, A, Mayer-Sonnenfeld, T, Frank, C, Olver, CS, Lencioni, AM, Dusto, NL, Tal, A, Har-Noy, M, Lillehei, KO, Katsanis, E & Graner, MW 2013, 'Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine', International Journal of Hyperthermia, vol. 29, no. 5, pp. 390-398. https://doi.org/10.3109/02656736.2013.800997
Epple, Laura M. ; Bemis, Lynne T. ; Cavanaugh, Ryan P. ; Skope, Anne ; Mayer-Sonnenfeld, Tehila ; Frank, Chad ; Olver, Christine S. ; Lencioni, Alex M. ; Dusto, Nathaniel L. ; Tal, Alona ; Har-Noy, Michael ; Lillehei, Kevin O. ; Katsanis, Emmanuel ; Graner, Michael W. / Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. In: International Journal of Hyperthermia. 2013 ; Vol. 29, No. 5. pp. 390-398.
@article{0ff64d10eee4438da6393f0cd0f4aec8,
title = "Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine",
abstract = "Purpose: This paper presents the treatment of a 12-year-old female spayed Great Dane who presented with vestibular signs (ataxia, nystagmus, hind end collapse). Thoracic radiographs revealed a discrete pulmonary nodule in the right cranial lung lobe. Ultrasound-guided fine needle aspirate detected primary bronchoalveolar adenocarcinoma, verified via computed tomography, with a second smaller nodule discovered in the right cranial lung lobe. Materials and methods: A lateral thoracotomy with right cranial lung lobectomy was performed. Histopathological analysis of the nodules and an excised lymph node identified grade III bronchoalveolar adenocarcinoma with vascular infiltration and lymph node metastasis-a grim diagnosis with a reported median survival time of 6-27 days. A 10-g sample of the tumour was processed into a chaperone-rich cell lysate (CRCL) vaccine, which was administered weekly to the patient. Imiquimod-a Toll-like receptor 7 (TLR7) agonist-was applied topically for the first 12 treatments to stimulate local Langerhans cells. A single injection of bacillus Calmette-Guerin (BCG) was administered for additional immune stimulation at week 30 of treatment. Results: The dog remained stable and in otherwise good health until diffuse relapse occurred 44 weeks after the initial treatment; following gastrointestinal bleeding, the dog was euthanised 50+ weeks post diagnosis. Conclusion: To the authors' knowledge, this is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case report suggests that CRCL vaccine combined with topical imiquimod is a safe, effective treatment for canine tumours.",
keywords = "Cancer vaccine, Canine lung tumour, Chaperone-rich cell lysate, Heat shock proteins, Tumour immunity",
author = "Epple, {Laura M.} and Bemis, {Lynne T.} and Cavanaugh, {Ryan P.} and Anne Skope and Tehila Mayer-Sonnenfeld and Chad Frank and Olver, {Christine S.} and Lencioni, {Alex M.} and Dusto, {Nathaniel L.} and Alona Tal and Michael Har-Noy and Lillehei, {Kevin O.} and Emmanuel Katsanis and Graner, {Michael W.}",
year = "2013",
month = "8",
doi = "10.3109/02656736.2013.800997",
language = "English (US)",
volume = "29",
pages = "390--398",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

AU - Epple, Laura M.

AU - Bemis, Lynne T.

AU - Cavanaugh, Ryan P.

AU - Skope, Anne

AU - Mayer-Sonnenfeld, Tehila

AU - Frank, Chad

AU - Olver, Christine S.

AU - Lencioni, Alex M.

AU - Dusto, Nathaniel L.

AU - Tal, Alona

AU - Har-Noy, Michael

AU - Lillehei, Kevin O.

AU - Katsanis, Emmanuel

AU - Graner, Michael W.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: This paper presents the treatment of a 12-year-old female spayed Great Dane who presented with vestibular signs (ataxia, nystagmus, hind end collapse). Thoracic radiographs revealed a discrete pulmonary nodule in the right cranial lung lobe. Ultrasound-guided fine needle aspirate detected primary bronchoalveolar adenocarcinoma, verified via computed tomography, with a second smaller nodule discovered in the right cranial lung lobe. Materials and methods: A lateral thoracotomy with right cranial lung lobectomy was performed. Histopathological analysis of the nodules and an excised lymph node identified grade III bronchoalveolar adenocarcinoma with vascular infiltration and lymph node metastasis-a grim diagnosis with a reported median survival time of 6-27 days. A 10-g sample of the tumour was processed into a chaperone-rich cell lysate (CRCL) vaccine, which was administered weekly to the patient. Imiquimod-a Toll-like receptor 7 (TLR7) agonist-was applied topically for the first 12 treatments to stimulate local Langerhans cells. A single injection of bacillus Calmette-Guerin (BCG) was administered for additional immune stimulation at week 30 of treatment. Results: The dog remained stable and in otherwise good health until diffuse relapse occurred 44 weeks after the initial treatment; following gastrointestinal bleeding, the dog was euthanised 50+ weeks post diagnosis. Conclusion: To the authors' knowledge, this is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case report suggests that CRCL vaccine combined with topical imiquimod is a safe, effective treatment for canine tumours.

AB - Purpose: This paper presents the treatment of a 12-year-old female spayed Great Dane who presented with vestibular signs (ataxia, nystagmus, hind end collapse). Thoracic radiographs revealed a discrete pulmonary nodule in the right cranial lung lobe. Ultrasound-guided fine needle aspirate detected primary bronchoalveolar adenocarcinoma, verified via computed tomography, with a second smaller nodule discovered in the right cranial lung lobe. Materials and methods: A lateral thoracotomy with right cranial lung lobectomy was performed. Histopathological analysis of the nodules and an excised lymph node identified grade III bronchoalveolar adenocarcinoma with vascular infiltration and lymph node metastasis-a grim diagnosis with a reported median survival time of 6-27 days. A 10-g sample of the tumour was processed into a chaperone-rich cell lysate (CRCL) vaccine, which was administered weekly to the patient. Imiquimod-a Toll-like receptor 7 (TLR7) agonist-was applied topically for the first 12 treatments to stimulate local Langerhans cells. A single injection of bacillus Calmette-Guerin (BCG) was administered for additional immune stimulation at week 30 of treatment. Results: The dog remained stable and in otherwise good health until diffuse relapse occurred 44 weeks after the initial treatment; following gastrointestinal bleeding, the dog was euthanised 50+ weeks post diagnosis. Conclusion: To the authors' knowledge, this is the first report of significantly prolonged survival following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a canine patient. This case report suggests that CRCL vaccine combined with topical imiquimod is a safe, effective treatment for canine tumours.

KW - Cancer vaccine

KW - Canine lung tumour

KW - Chaperone-rich cell lysate

KW - Heat shock proteins

KW - Tumour immunity

UR - http://www.scopus.com/inward/record.url?scp=84881146403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881146403&partnerID=8YFLogxK

U2 - 10.3109/02656736.2013.800997

DO - 10.3109/02656736.2013.800997

M3 - Article

C2 - 23786302

AN - SCOPUS:84881146403

VL - 29

SP - 390

EP - 398

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 5

ER -